Gene Therapy Immunogenicity - Virtual Summit

Immunogenicity compromises both the efficacy and safety of gene therapies and thus represents one of the most prominent challenges that must be overcome in the field. Uniting translational, clinical, regulatory and manufacturing gene therapy functions, the inaugural Gene Therapy Immunogenicity Summit is the industry's definitive meeting enabling you to better measure, modulate and predict immune response and drive transformative treatments through the clinic to patients more quickly and efficiently.

Key topics of discussion include:
Evaluating the suitability and success of current immunosuppression agents in the context of gene therapy
Employing risk assessment tools to develop clinical bioanalytical and immunogenicity monitoring strategies
Dissecting the immunogenicity of gene therapy vectors to better understand immunology safety concerns
Better understanding the innate immune response and its implications for gene therapy transduction
Evaluating the resolution and throughput of technologies to define empty vs full capsid presence
Implementing the use of preclinical risk assessment tools to drive clinical immunogenicity strategies for gene therapy modalities
What the implications are for the safety and efficacy of gene therapies if re-dosing is to occur

Others Details

URL: Brochure: https://go.evvnt.com/614539-3?pid=6581 Speakers: Barry Byrne, Professor and Associate Chairman, University of Florida, Mark Milton, Area Head of Ophthalmology, Novartis, Sander van Deventer, Executive Vice President, uniQure, Martin Childers, Chief Medical Officer, Asklepios BioPharmaceutical, Roland Herzog, Professor of Pediatrics, Indiana University School of Medicine, Klaudia Kuranda, Immunology Leader, Spark Therapeutics and more. Time: 08:00 - 17:30